Cargando…
Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
AIMS: Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point‐of‐care tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot ulcers: venous white cell count, C‐reactive protein (CRP)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811820/ https://www.ncbi.nlm.nih.gov/pubmed/28734103 http://dx.doi.org/10.1111/dme.13431 |
_version_ | 1783299926264905728 |
---|---|
author | Ingram, J. R. Cawley, S. Coulman, E. Gregory, C. Thomas‐Jones, E. Pickles, T. Cannings‐John, R. Francis, N. A. Harding, K. Hood, K. Piguet, V. |
author_facet | Ingram, J. R. Cawley, S. Coulman, E. Gregory, C. Thomas‐Jones, E. Pickles, T. Cannings‐John, R. Francis, N. A. Harding, K. Hood, K. Piguet, V. |
author_sort | Ingram, J. R. |
collection | PubMed |
description | AIMS: Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point‐of‐care tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot ulcers: venous white cell count, C‐reactive protein (CRP) and procalcitonin, and a novel wound exudate calprotectin assay. Calprotectin is a marker of neutrophilic inflammation. METHODS: In a prospective study, people with uninfected or mildly infected diabetic foot ulcers who had not received oral antibiotics in the preceding 2 weeks were recruited from community podiatry clinics for measurement of inflammatory biomarkers. Antibiotic prescribing decisions were based on clinicians’ baseline assessments and participants were reviewed 1 week later; ulcer infection was defined by clinicians’ overall impression from their two assessments. RESULTS: Some 363 potential participants were screened, of whom 67 were recruited, 29 with mildly infected diabetic foot ulcers and 38 with no infection. One participant withdrew early in each group. Ulcer area was 1.32 cm(2) [interquartile range (IQR) 0.32–3.61 cm(2)] in infected ulcers and 0.22 cm(2) (IQR 0.09–1.46 cm(2)) in uninfected ulcers. Baseline CRP for mild infection was 9.00 mg/ml and 6.00 mg/ml for uninfected ulcers; most procalcitonin levels were undetectable. Median calprotectin level in infected diabetic foot ulcers was 1437 ng/ml and 879 ng/ml in uninfected diabetic foot ulcers. Area under the receiver operating characteristic curve for a composite algorithm incorporating calprotectin, CRP, white cell count and ulcer area was 0.68 (95% confidence intervals 0.52–0.82), sensitivity 0.64, specificity 0.81. CONCLUSIONS: A composite algorithm including CRP, calprotectin, white cell count and ulcer area may help to distinguish uninfected from mildly infected diabetic foot ulcers. Venous procalcitonin is unhelpful for mild diabetic foot ulcer infection. |
format | Online Article Text |
id | pubmed-5811820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58118202018-02-16 Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) Ingram, J. R. Cawley, S. Coulman, E. Gregory, C. Thomas‐Jones, E. Pickles, T. Cannings‐John, R. Francis, N. A. Harding, K. Hood, K. Piguet, V. Diabet Med Research Articles AIMS: Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point‐of‐care tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot ulcers: venous white cell count, C‐reactive protein (CRP) and procalcitonin, and a novel wound exudate calprotectin assay. Calprotectin is a marker of neutrophilic inflammation. METHODS: In a prospective study, people with uninfected or mildly infected diabetic foot ulcers who had not received oral antibiotics in the preceding 2 weeks were recruited from community podiatry clinics for measurement of inflammatory biomarkers. Antibiotic prescribing decisions were based on clinicians’ baseline assessments and participants were reviewed 1 week later; ulcer infection was defined by clinicians’ overall impression from their two assessments. RESULTS: Some 363 potential participants were screened, of whom 67 were recruited, 29 with mildly infected diabetic foot ulcers and 38 with no infection. One participant withdrew early in each group. Ulcer area was 1.32 cm(2) [interquartile range (IQR) 0.32–3.61 cm(2)] in infected ulcers and 0.22 cm(2) (IQR 0.09–1.46 cm(2)) in uninfected ulcers. Baseline CRP for mild infection was 9.00 mg/ml and 6.00 mg/ml for uninfected ulcers; most procalcitonin levels were undetectable. Median calprotectin level in infected diabetic foot ulcers was 1437 ng/ml and 879 ng/ml in uninfected diabetic foot ulcers. Area under the receiver operating characteristic curve for a composite algorithm incorporating calprotectin, CRP, white cell count and ulcer area was 0.68 (95% confidence intervals 0.52–0.82), sensitivity 0.64, specificity 0.81. CONCLUSIONS: A composite algorithm including CRP, calprotectin, white cell count and ulcer area may help to distinguish uninfected from mildly infected diabetic foot ulcers. Venous procalcitonin is unhelpful for mild diabetic foot ulcer infection. John Wiley and Sons Inc. 2017-08-15 2018-02 /pmc/articles/PMC5811820/ /pubmed/28734103 http://dx.doi.org/10.1111/dme.13431 Text en © 2017 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Ingram, J. R. Cawley, S. Coulman, E. Gregory, C. Thomas‐Jones, E. Pickles, T. Cannings‐John, R. Francis, N. A. Harding, K. Hood, K. Piguet, V. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) |
title | Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) |
title_full | Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) |
title_fullStr | Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) |
title_full_unstemmed | Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) |
title_short | Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) |
title_sort | levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (induce study) |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811820/ https://www.ncbi.nlm.nih.gov/pubmed/28734103 http://dx.doi.org/10.1111/dme.13431 |
work_keys_str_mv | AT ingramjr levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT cawleys levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT coulmane levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT gregoryc levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT thomasjonese levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT picklest levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT canningsjohnr levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT francisna levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT hardingk levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT hoodk levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy AT piguetv levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy |